EUCAST Technical Note on Voriconazole and Aspergillus spp.

被引:41
作者
Hope, W. W. [1 ]
Cuenca-Estrella, M. [2 ]
Lass-Floerl, C. [3 ]
Arendrup, M. C. [4 ]
机构
[1] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[2] Inst Salud Carlos III, Serv Micol, Mahadahonda, Spain
[3] Med Univ Innsbruck, A-6020 Innsbruck, Austria
[4] Statens Serum Inst, Unit Mycol, DK-2300 Copenhagen, Denmark
关键词
Breakpoints; EUCAST Technical Note; itraconazole; amphotericin; posaconazole; Aspergillus; susceptibility testing; TO-ORAL SWITCH; INVASIVE ASPERGILLOSIS; HEALTHY-ADULTS; SAFETY; PHARMACOKINETICS; EFFICACY; MODEL;
D O I
10.1111/1469-0691.12148
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for voriconazole against Aspergillus spp. This Technical Note is based on the EUCAST rationale document for voriconazole (available on the EUCAST website: http://www.eucast.org). Voriconazole breakpoints are based on epidemiological cut-off values, pharmacokinetic/pharmacodynamic data and clinical experience. Breakpoints will be reviewed regularly or when new data emerge.
引用
收藏
页码:E278 / E280
页数:3
相关论文
共 11 条
[1]  
[Anonymous], 2008, CLIN MICROBIOL INFEC, V14, P985
[2]   Therapy for fungal diseases: opportunities and priorities [J].
Denning, David W. ;
Hope, William W. .
TRENDS IN MICROBIOLOGY, 2010, 18 (05) :195-204
[3]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[4]   Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults [J].
Driscoll, Timothy A. ;
Yu, Lolie C. ;
Frangoul, Haydar ;
Krance, Robert A. ;
Nemecek, Eneida ;
Blumer, Jeffrey ;
Arrieta, Antonio ;
Graham, Michael L. ;
Bradfield, Scott M. ;
Baruch, Alice ;
Liu, Ping .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) :5770-5779
[5]   Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Adolescents and Healthy Adults [J].
Driscoll, Timothy A. ;
Frangoul, Haydar ;
Nemecek, Eneida R. ;
Murphey, Donald K. ;
Yu, Lolie C. ;
Blumer, Jeffrey ;
Krance, Robert A. ;
Baruch, Alice ;
Liu, Ping .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) :5780-5789
[6]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[7]   Population Pharmacokinetics of Voriconazole in Adults [J].
Hope, William W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :526-531
[8]   Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints [J].
Jeans, Adam R. ;
Howard, Susan J. ;
Al-Nakeeb, Zaid ;
Goodwin, Joanne ;
Gregson, Lea ;
Majithiya, Jayesh B. ;
Lass-Floerl, Cornelia ;
Cuenca-Estrella, Manuel ;
Arendrup, Maiken C. ;
Warn, Peter A. ;
Hope, William W. .
JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (03) :442-452
[9]   Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis [J].
Mavridou, Eleftheria ;
Bruggemann, Roger J. M. ;
Melchers, Willem J. G. ;
Verweij, Paul E. ;
Mouton, Johan W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) :4758-4764
[10]   Voriconazole Pharmacokinetics and Pharmacodynamics in Children [J].
Neely, Michael ;
Rushing, Teresa ;
Kovacs, Andrea ;
Jelliffe, Roger ;
Hoffman, Jill .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) :27-36